Trial Profile
An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2018
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Adverse reactions
- Acronyms B-Confident
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 16 Jun 2018 Results (n=285) of long-term safety of different canakinumab doses across different age groups (<4 to 65 years) in patients with CAPS and other auto inflammatory syndromes, presented at the 19th Annual Congress of the European League Against Rheumatism.
- 17 Jun 2017 Results (n=68) presented at the 18th Annual Congress of the European League Against Rheumatism.